Full-Time

Strategic Partnership Manager

Posted on 8/23/2025

Altasciences

Altasciences

1,001-5,000 employees

Integrated CRO for early-phase drug development

Compensation Overview

$100k - $130k/yr

Laval, QC, Canada + 1 more

More locations: Overland Park, KS, USA

In Person

Category
Sales & Account Management (1)
Required Skills
Google Cloud Platform
Requirements
  • Master’s degree or Ph. D. in Sciences. Equivalent fields and / or equivalent experience could be considered.
  • Minimum of 15 years of Clinical or Nonclinical research experience required including at least 10 years in Project Management
  • Professional attitude and strong interpersonal skills.
  • Ability to work well with a multi-disciplinary team of professionals.
  • Client-focused approach.
  • Solution-focus and ability to creatively solve problems and resolve issues.
  • Ability to take initiative and use sound judgement.
  • Ability to acquire and apply knowledge quickly.
  • Flexible attitude with an ability to effectively prioritize.
  • Understanding of early-stage drug development process and applicable regulatory guidelines.
  • Knowledge of regulatory guidelines for preclinical and clinical studies as well as GCP and GLP procedures.
  • Business acumen.
  • Excellent communication skills in French and English (written and oral)
  • Proficiency in Smartsheet
Responsibilities
  • Cross service portfolio oversight and tracking.
  • Partners with BD and executive leadership on client strategy by optimizing customer intelligence through relationship management.
  • Facilitates multi-site connectivity to optimize work schedules and resources.
  • Uses autonomy and strong interpersonal skills to liaise between departmental teams and the Sponsor to ensure Sponsor requirements, scope and milestones are understood and met.
  • Acts as centralized point of escalation for internal and external stakeholders with responsibility to ensure the executive leadership team are informed of issues and partnership status.
  • Develops and maintains appropriate tools, such as customized timelines and workflows, shared portfolio trackers and dashboards in collaboration with Program and Project Managers.
  • Coordinates, prepares for and facilitates joint operational committee - Governance meetings and helps coordinate and participates in executive business review meetings, as appropriate.
  • Serves as an advocate for both the Sponsor and Altasciences, proactively engaging in issue resolution and leveraging influence to standardize and align processes across teams and sites that optimize workflows for both parties.
  • Is aware of and communicates client expectations and requirements across business divisions, as applicable.
  • Supports internal and external engagement in the company-wide commitment to Tell Us OnceTM through reinforcement of and adherence to the Ask Albert policy.
  • Leads/Contributes to appropriate team meeting agendas, presentations, and discussions.
  • Consolidates monthly metrics and status updates on key Sponsors.
  • Collaborates with Quality Assurance to ensure compliance is maintained and audit requests or findings are adequately addressed.
  • Assists in providing content for RFPs.
  • Participate in client visits, or host clients, as required.
  • Aids Business Development in promoting Altasciences' services; creates content, participates, and presents at Bid Defense and Capabilities Presentations.
  • Supports identification of Sponsors requiring partnership or program support.
  • Support the expansion of additional services needed to support strategic clients through garnered customer intelligence.
  • Attends appropriate conferences to meet with current Sponsor or identify potential Sponsors.

Altasciences provides an integrated CRO that handles the full early‑phase drug development path, from preclinical testing through clinical proof of concept and into manufacturing. Its approach combines discovery support, safety testing, clinical trial execution, and in‑house manufacturing to run programs under one roof. This contrasts with competitors that require pharma and biotech clients to source services from multiple vendors, adding complexity and risk; Altasciences streamlines the process by coordinating all steps. The company aims to help innovator drug programs move quickly and efficiently, delivering integrated data to de‑risk decisions and speed progression to later stages.

Company Size

1,001-5,000

Company Stage

Early VC

Total Funding

$6.7M

Headquarters

Laval, Canada

Founded

1976

Simplify Jobs

Simplify's Take

What believers are saying

  • Biotech/pharma consolidation demand for single-vendor early-phase development solutions increases.
  • 3D tissue technology adoption reduces animal testing costs and accelerates regulatory approval timelines.
  • Geographic footprint and participant database enable rapid enrollment for mid-size biopharma sponsors.

What critics are saying

  • Novo Holdings divesting Altasciences signals poor financial performance and operational cutbacks.
  • Charles River aggressive pricing on integrated packages captures 20% mid-size biopharma contracts.
  • AI-driven preclinical platforms from Insilico Medicine displace traditional animal safety pharmacology testing.

What makes Altasciences unique

  • Integrated CRO/CDMO spanning preclinical safety testing through Phase IV bioanalysis and manufacturing.
  • 9 North American facilities with 500,000+ participant database conducting 285+ trials annually.
  • VoxCell partnership integrates 3D tissue technology for human-relevant preclinical testing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Employee Assistance & Telehealth Programs

Remote Work Options

Company News

GlobeNewswire
Mar 16th, 2026
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

ISELIN, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard...

Business Wire
Aug 20th, 2025
Altasciences Receives EcoVadis Gold Medal for Environmental, Social, and Governance (ESG) Efforts

EcoVadis, the world's most trusted provider of business sustainability ratings, has collaborated closely with Altasciences to enhance its environmental, social, and governance (ESG) initiatives, underscoring the company's commitment to a sustainable future and a reduced environmental footprint.

Yahoo Finance
Jul 31st, 2025
Altasciences and VoxCell BioInnovation Announce Strategic Collaboration to Advance Preclinical Drug Development

This partnership combines Altasciences' comprehensive early-phase drug development capabilities with VoxCell's cutting-edge 3D tissue technology to offer a more predictive and human-relevant preclinical testing environment.

Postmedia Network
Mar 28th, 2025
Altasciences Receives 2025 CDMO Leadership Award in Small Molecule Dosage Form Category

For 14 years, Outsourced Pharma's CDMO Leadership Awards have recognized the top-performing contract development and manufacturing organizations based on comprehensive industry research, and feedback from sponsors.

BioSpace
May 29th, 2024
Altasciences Receives 2024 CRO Leadership Award for Capabilities

Altasciences receives 2024 CRO Leadership Award for Capabilities.

INACTIVE